Common Interest Doctrine and Attorney-Client Privilege Protect Distributor’s Email Communication with Defendant

Feb 3, 2020

Reading Time : 1 min

Plaintiff, Beijing Choice Electronic Technology Co., Ltd. (“Choice”) sued Contec Medical Systems USA, Inc. and Contec Medical Systems Co., Ltd. (collectively, “Contec”) for infringing Choice’s patents related to fingertip pulse oximeters. After the complaint had been filed, an attorney for Choice sent cease-and-desist letters to six Contec distributors, including Veridian Healthcare LLC (“Veridian”). Veridian, in turn, sought advice via email from Contec regarding how best to respond to the cease-and-desist letter. Choice subpoenaed Veridian documents, including its emails and later moved to compel production after Veridian withheld the material on the basis of attorney-client privilege.

The court held that privilege attached to a single email—a filtered summary of an attorney’s opinions regarding the litigation that was primarily legal in nature. The court also found the document implicated the common interest doctrine. Veridian purchased oximeters from Contec that were at the center of the litigation, and after receiving the cease-and-desist letter, Veridian reasonably understood it might face its own lawsuit for selling the allegedly infringing products. The document thus concerned coordination between Veridian and Contec, both of which had an actual legal interest in avoiding liability. Because the privileged status of communications falling within the common interest doctrine cannot be waived without the consent of all parties, the court found the document properly withheld as privileged.

The court held that the remaining documents were not protected by the attorney-client privilege or work product immunity. The court determined the documents did not reveal the substance of any client confidence or opinions of Contec’s counsel. Instead, the documents involved business discussions. As such, the court ordered Veridian to produce them.

Beijing Choice Elec. Tech. Co. v. Contec Med. Sys. USA, Inc., No. 1:18-CV-825, D.I. 182 (N.D. Ill. Jan. 14, 2020)

Share This Insight

Previous Entries

IP Newsflash

December 9, 2025

The Federal Circuit recently denied a petition for a writ of mandamus that challenged the PTO Director’s reliance on “settled expectations” to discretionarily deny two inter partes review (IPR) petitions. In so doing, the court explained that, while it was not deciding whether the Director’s use of “settled expectations” was correct, the petitioner’s arguments about what factors the Director may consider when deciding whether to institute an IPR or post-grant review (PGR) are not generally reviewable and did not provide sufficient basis for mandamus review here.

...

Read More

IP Newsflash

December 5, 2025

District courts are split on whether a complaint can provide the required knowledge for post-suit indirect and willful infringement in that same lawsuit. Chief Judge Connolly in the District of Delaware recently confirmed that, consistent with his prior opinions, the complaint cannot serve as the basis for knowledge for either a claim of post-suit indirect infringement or a demand for willfulness-based enhanced damages in that lawsuit.

...

Read More

IP Newsflash

December 3, 2025

The Federal Circuit recently held that a patentee acted as its own lexicographer to define a claim term even though it did not explicitly define the term. Rather, because the patentee consistently and clearly used two terms interchangeably to describe the same structural feature and did so in all of the embodiments in which the feature appeared, the patentee impliedly gave the term its own, unique definition.

...

Read More

IP Newsflash

December 2, 2025

The Federal Circuit recently held an asserted patent was not entitled to its priority date because the priority application lacked written description support for the asserted claims. In so doing, the court explained that broad disclosures that do not provide reasonably specific support for narrower claims do not meet the written description requirement. The court also considered whether the inventor’s testimony showed they possessed the full scope of the claimed genus at the priority date or whether it was more likely the inventors first became aware of the claimed embodiments from public disclosures of the accused product.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.